Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating

Abbott Laboratories (NYSE:ABT) is one of the top low volatility healthcare stocks to buy now. Analyst Mike Kratky from Leerink Partners reiterated a Hold rating on Abbott Laboratories (NYSE:ABT) on July 21, decreasing the price target to $136.00 from $143.00.

The analyst justified the Hold rating with the company’s performance, stating that Abbott Laboratories’ (NYSE:ABT) recent Q2 earnings report presented a mixed picture.

Management slashed their organic sales growth guidance, attributed primarily to several headwinds collectively affecting the Diagnostics segment outlook. These include changes in HIV funding, disruptions from value-based purchasing (VBP) in China, and weaker-than-expected COVID-19 sales.

Kratky also stated that positive aspects for Abbott Laboratories (NYSE:ABT) exist amid these challenges, especially in the company’s MedTech segment, which delivered solid growth. The non-MedTech segments are, however, continually facing complications, warranting a cautious outlook as these segments contribute significantly to the company’s revenue.

Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells healthcare products. Its business segments include Diagnostic Products, Established Pharmaceutical Products, Medical Devices, and Nutritional Products. The company’s Abbott Molecular is a leader in oncology molecular diagnostics with its Vysis FISH assays.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.